Hepatitis D revival

More than 30 years after Mario Rizzetto and colleagues described a new antigen in livers of HBsAg‐positive patients called the “delta antigen”, a re‐emerging interest in hepatitis delta is currently observed. The state‐of‐the art on basic and clinical research on hepatitis delta was presented during a monothematic conference organized by the European Association for the Study of the Liver (EASL) in September 2010. Hepatitis delta is caused by infection with the hepatitis D virus (HDV) which requires presence of HBsAg for complete replication and transmission. Recent data confirmed the severe long‐term course of HDV infection with high rates of hepatic decompensation while controversial data on the risk for the development of hepatocellular carcinoma were reported. Pegylated interferon alpha can lead to sustained HDV RNA elimination in about one quarter of patients while HBV polymerase inhibitors are ineffective against HDV. Novel treatment options include prenylation inhibitors and HBV entry inhibitors which are currently in early clinical development.

[1]  A. Andriulli,et al.  Outcome of chronic delta hepatitis in Italy: a long-term cohort study. , 2010, Journal of hepatology.

[2]  L. Kucirka,et al.  Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. , 2010, The Journal of infectious diseases.

[3]  H. Wedemeyer,et al.  Hepatitis Delta: Immunopathogenesis and Clinical Challenges , 2010, Digestive Diseases.

[4]  M. Manns,et al.  Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics , 2010, Journal of Clinical Microbiology.

[5]  M. Manns,et al.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead , 2010, Nature Reviews Gastroenterology &Hepatology.

[6]  H. Tillmann,et al.  Virological and clinical characteristics of delta hepatitis in Central Europe , 2009, Journal of viral hepatitis.

[7]  M. Colombo,et al.  A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. , 2009, Gastroenterology.

[8]  H. Wedemeyer,et al.  Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges? , 2009, Annals of hepatology.

[9]  V. Pazienza,et al.  Hepatitis delta virus inhibits alpha interferon signaling , 2009, Hepatology.

[10]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[11]  C. Yurdaydın,et al.  Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta‐analysis , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[12]  M. Hussain,et al.  The increasing prevalence of hepatitis delta virus (HDV) infection in South London , 2008, Journal of medical virology.

[13]  C. Toro,et al.  Does Treatment of Hepatitis B virus (HBV) Infection Reduce Hepatitis Delta virus (HDV) Replication in HIV-HBV-HDV-Coinfected Patients? , 2008, Antiviral therapy.

[14]  V. Soriano,et al.  Liver cirrhosis in HIV‐infected patients: prevalence, aetiology and clinical outcome , 2007, Journal of viral hepatitis.

[15]  H. Wedemeyer,et al.  Clearance of Chronic HCV Infection During Acute Delta Hepatitis , 2009, Infection.

[16]  M. Manns,et al.  [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. , 2007, Zeitschrift fur Gastroenterologie.

[17]  M. Manns,et al.  Hepatitis D virus infection—Not a vanishing disease in Europe! , 2007, Hepatology.

[18]  M. Manns,et al.  [4] 72 WEEK DATA OF THE HIDIT-1 TRIAL: A MULTICENTER RANDOMISED STUDY COMPARING PEGINTERFERON α-2a PLUS ADEFOVIR VS. PEGINTERFERON α-2a PLUS PLACEBO VS. ADEFOVIR IN CHRONIC DELTA HEPATITIS , 2007 .

[19]  Pei-Jer Chen,et al.  Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  P. Lopalco,et al.  Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon‐α2b , 2006 .

[22]  A. Andriulli,et al.  Pegylated interferon alpha‐2b as monotherapy or in combination with ribavirin in chronic hepatitis delta , 2006, Hepatology.

[23]  P. Marcellin,et al.  Efficacy of peginterferon alpha‐2b in chronic hepatitis delta: Relevance of quantitative RT‐PCR for follow‐up , 2006, Hepatology.

[24]  C. Yurdaydın,et al.  Cytotoxic CD4+ T cells in viral hepatitis , 2006, Journal of viral hepatitis.

[25]  Shou-Dong Lee,et al.  Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. , 2006, Gastroenterology.

[26]  T. Nishizawa,et al.  Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia , 2006, Journal of medical virology.

[27]  M. Manns,et al.  479 Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the Hep-Net/international HDV intervention trial , 2006 .

[28]  C. Yurdaydın.  Delta hepatitis in Turkey: decreasing but not vanishing and still of concern. , 2006, The Turkish Journal of Gastroenterology.

[29]  P. Pontisso,et al.  Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients , 2006, Hepatology.

[30]  D. Häussinger,et al.  Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[31]  C. K. Chu,et al.  Clevudine Inhibits Hepatitis Delta Virus Viremia: a Pilot Study of Chronically Infected Woodchucks , 2005, Antimicrobial Agents and Chemotherapy.

[32]  U. Akarca,et al.  Two-Year Interferon Therapy with Or without Ribavirin in Chronic Delta Hepatitis , 2005, Antiviral therapy.

[33]  M. Rizzetto,et al.  Treatment of hepatitis D , 2005, Journal of viral hepatitis.

[34]  R. Purcell,et al.  Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. , 2004, Gastroenterology.

[35]  M. Milinkovitch,et al.  Molecular Phylogenetic Analyses Indicate a Wide and Ancient Radiation of African Hepatitis Delta Virus, Suggesting a Deltavirus Genus of at Least Seven Major Clades , 2004, Journal of Virology.

[36]  C. Yurdaydın,et al.  Risk Factors for Hepatocellular Carcinoma in Turkey , 2001, Digestive Diseases and Sciences.

[37]  Ping Liu,et al.  In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. , 2003, The Journal of clinical investigation.

[38]  D. Häussinger,et al.  Socioepidemiological Data on Hepatitis Delta in a German University Clinic - Increase in Patients from Eastern Europe and the Former Soviet Union , 2003, Zeitschrift fur Gastroenterologie.

[39]  M. Manns,et al.  Famciclovir treatment of chronic delta hepatitis. , 2002, Journal of hepatology.

[40]  M. Buti,et al.  Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference , 2001, Hepatology.

[41]  E. Sagnelli,et al.  Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis , 2000, Hepatology.

[42]  E. Sagnelli,et al.  Chronic hepatitis D: A vanishing disease? An Italian multicenter study , 2000, Hepatology.

[43]  A. Kidd,et al.  Recent High Incidence of Fulminant Hepatitis in Samara, Russia: Molecular Analysis of Prevailing Hepatitis B and D Virus Strains , 2000, Journal of Clinical Microbiology.

[44]  M. Rizzetto.  Hepatitis D: virology, clinical and epidemiological aspects. , 2000, Acta gastro-enterologica Belgica.

[45]  S. Hadziyannis.  REVIEW: Hepatitis delta , 1997, Journal of gastroenterology and hepatology.

[46]  M. Houghton,et al.  Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles , 1997, Journal of virology.

[47]  K. Hyams,et al.  Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. , 1996, The Journal of infectious diseases.

[48]  M. Rizzetto,et al.  Ribavirin treatment for chronic hepatitis D: a pilot study. , 2008, Liver.

[49]  P. van Eyken,et al.  Treatment of chronic hepatitis D with interferon alfa-2a. , 1994, The New England journal of medicine.

[50]  H. Handa,et al.  Hepatitis Delta Virus , 2006 .

[51]  R. Purcell,et al.  The significance of infections with two types of viral hepatitis demonstrated by histologic features in chimpanzees. , 1990, Journal of hepatology.

[52]  G. Fattovich,et al.  Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. , 1987, The Journal of infectious diseases.

[53]  R. Purcell,et al.  delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Purcell,et al.  INCIDENCE AND SIGNIFICANCE OF ANTIBODIES TO DELTA ANTIGEN IN HEPATITIS B VIRUS INFECTION , 1979, The Lancet.

[55]  M. Rizzetto,et al.  Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. , 1977, Gut.

[56]  J. Mackeith.  DISCHARGE OF VIOLENT PATIENTS , 1975, The Lancet.

[57]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .